Mindray Medical International Limited (NYSE:MR)

We are starting to see higher highs and higher lows over the past few weeks. I believe this trend will continue as we come into the summer months. I think this one has a long way to run.
g

This company is in the right place at the right time

(JJ) Good earnings growth, well positioned to continue growing in an emerging market. Credible accounting.

Zacks article

With PricewaterhouseCoopers as its audit firm, there's much less of a concern about the integrity of the financial reports as is the case with other China based companies. I see this stock doing well when China stocks swing in favor. And I am putting my money where my mouth is...I invested today...this takes the China spot in my portfolio.

oversold.

I'm in China often. The level of medical care needs strong infrastructure improvement, including equipment. I'm surprised the China government hasn't put this as one of their very high priorities. MR will be poised to take advantage when this focus happens.

rule breakers

Nice safety at these entry points. Nice upside potential probable in coming year.

After adjusting the share price downward to reflect the company's net cash position of $3.70 per share, I calculate that Mindray Medical is selling for about 14 times its forward eps. Considering this company's impressive operations history and outstanding growth prospects as a Chinese maker of medical devices, this seems like a deal. The auditor is Price Waterhouse Coopers - so not much chance of fraud.

Paying off debt, rising sales, constant profit growth.

Stock screen results. Using ROE, PE, LT debt/Equity, Current Ratio.

killtheump china play pick plus a teeny tiny dividend.
Catching it a the bottom?

In 2010 the market hasn't been kind to stocks that only meet or slightly beat earnings estimates. Consider MR who analysts had pegged at $.34/share in the second quarter. Actual earnings come in at $.36/share and the stock gets drubbed to the tune of 15%. The international revenue was responsible for most of this as revenue in China dropped slightly. MR is now trading at about 19 times trailing earnings and 16 times 2011 projected earnings. Both are historically low and offer investors a great opportunity -- one that I just took advantage of.

you know why.....

another good chinese story in healthcare

This stock, while haveing a dividend. Is not high enoght to buy right now. Have to wait for a while

gh

Chinese medical equipment supplier. I am going to hold my breath and not buy into the stereotype that everything made in China is bad. As the median age continues to increase, Chinese are going to have to spend their savings on something, and it is as likely to be medical care as education.